92 related articles for article (PubMed ID: 23346831)
1. [How I explore ... a risk difference in the occurrence of an event in clinical trials].
Scheen AJ; Ernest P; Jandrain B
Rev Med Liege; 2012 Nov; 67(11):597-602. PubMed ID: 23346831
[TBL] [Abstract][Full Text] [Related]
2. [Risk and odds--how to calculate with events].
Malmquist J
Lakartidningen; 2002 Feb; 99(8):751-3, 756. PubMed ID: 11894612
[TBL] [Abstract][Full Text] [Related]
3. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of therapeutic efficacy, an essential step in evidence-based medicine].
Scheen AJ
Rev Med Liege; 2000 Apr; 55(4):206-10. PubMed ID: 10909301
[TBL] [Abstract][Full Text] [Related]
5. From evidence-based medicine to personalized medicine, with particular emphasis on drug-safety monitoring.
Ennezat PV; Cosgrove S; Bouvaist H; Maréchaux S; Guerbaai RA; Le Jemtel T; Andréjak M; Vital-Durand D
Arch Cardiovasc Dis; 2017; 110(6-7):413-419. PubMed ID: 28552224
[TBL] [Abstract][Full Text] [Related]
6. Meaningful interpretation of risk reduction from clinical drug trials.
McCormack JP; Levine M
Ann Pharmacother; 1993 Oct; 27(10):1272-7. PubMed ID: 8251698
[TBL] [Abstract][Full Text] [Related]
7. Interpretation of absolute measures of disease risk in comparative research.
Replogle WH; Johnson WD
Fam Med; 2007 Jun; 39(6):432-5. PubMed ID: 17549653
[TBL] [Abstract][Full Text] [Related]
8. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
Carroll KJ
Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
[TBL] [Abstract][Full Text] [Related]
9. The use of putative placebo in active control trials: two applications in a regulatory setting.
Durrleman S; Chaikin P
Stat Med; 2003 Mar; 22(6):941-52. PubMed ID: 12627411
[TBL] [Abstract][Full Text] [Related]
10. Inhaled corticosteroids in children with persistent asthma: effects on growth.
Zhang L; Prietsch SO; Ducharme FM
Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
[TBL] [Abstract][Full Text] [Related]
11. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective.
Rosenblatt M
J Bone Miner Res; 2003 Jun; 18(6):1142-5. PubMed ID: 12817772
[TBL] [Abstract][Full Text] [Related]
12. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Ketter TA
Int J Clin Pract; 2013 May; 67(5):407-11. PubMed ID: 23574101
[TBL] [Abstract][Full Text] [Related]
13. Practical risk management in early phase clinical trials.
Coates S; Täubel J; Lorch U
Eur J Clin Pharmacol; 2019 Apr; 75(4):483-496. PubMed ID: 30569285
[TBL] [Abstract][Full Text] [Related]
14. Active-control trials with binary data: a comparison of methods for testing superiority or non-inferiority using the odds ratio.
Siqueira AL; Whitehead A; Todd S
Stat Med; 2008 Feb; 27(3):353-70. PubMed ID: 17628041
[TBL] [Abstract][Full Text] [Related]
15. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo.
Fisher LD; Gent M; Büller HR
Am Heart J; 2001 Jan; 141(1):26-32. PubMed ID: 11136483
[TBL] [Abstract][Full Text] [Related]
16. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
D'Agostino RB; Massaro JM; Sullivan LM
Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
[TBL] [Abstract][Full Text] [Related]
17. Relative vs. absolute measures of benefit and risk: what's the difference?
Citrome L
Acta Psychiatr Scand; 2010 Feb; 121(2):94-102. PubMed ID: 19694632
[TBL] [Abstract][Full Text] [Related]
18. A mixed approach for proving non-inferiority in clinical trials with binary endpoints.
Rousson V; Seifert B
Biom J; 2008 Apr; 50(2):190-204. PubMed ID: 18311852
[TBL] [Abstract][Full Text] [Related]
19. A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials.
Brittain E; Lin D
Stat Med; 2005 Jan; 24(1):1-10. PubMed ID: 15532089
[TBL] [Abstract][Full Text] [Related]
20. [Four numbers and basic knowledge of mathematics].
Suter K; Briel M; Günther J
Med Monatsschr Pharm; 2015 Jan; 38(1):12-6. PubMed ID: 26349120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
